Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
Completed
Astellas Pharma Inc
Phase 3
2008-04-25
The study is intended to test the safety, tolerability, efficacy of two doses of long term
once daily (qd) treatment of Mirabegron in patients with symptoms of overactive bladder and
secondly to compare these with active comparator.
Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
Completed
Astellas Pharma Inc
Phase 3
2008-04-28
The study is intended to test efficacy, safety and tolerability of two doses of Mirabegron
against placebo and compare the efficacy and safety with active comparator in patients with
symptoms of overactive bladder.
A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder
Completed
Astellas Pharma Europe B.V.
Phase 2
2011-03-29
The purpose of this study is to examine how well two medicines in combination (solifenacin
succinate and mirabegron) work in the treatment of bladder problems over a 12-week period.
A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.
Completed
Astellas Pharma Europe Ltd.
Phase 3
2012-06-12
The purpose of the study was to assess the efficacy, safety and tolerability of mirabegron 50
mg versus (vs) solifenacin 5 mg in the treatment of patients with OAB who were dissatisfied
with their treatment due to lack of efficacy.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
